The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | IMpower150: atezolizumab, chemotherapy and bevacizumab for NSCLC
Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, provides an update on the IMpower150 trial (NCT02366143) of atezolizumab, bevacizumab and chemotherapy for untreated, advanced non-small cell lung cancer. Prof. Reck highlights the exceedingly promising results and gives his insight into the responses of different subgroups of the trials. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
